Alnylam Launches “Alnylam P5x25” Strategy for Planned Transition to a Top Five Biotech in Market Capitalization Over Next Five Years 3 years ago [#item_full_content] Alnylam Announces New Advances in ATTR Amyloidosis ProgramDateMay 11, 2021In relation toSimilar postAlnylam’s Founding CEO John Maraganore To Exit The CompanyDateOctober 28, 2021In relation toSimilar postAlnylam to Webcast Presentations at Upcoming June Investor ConferencesDateMay 26, 2021In relation toSimilar post
